Endothelium-derived vasoconstriction by purines and pyrimidines.
Burnstock
Geoffrey
G
D000227:Adenine Nucleotides / Q000097:blood / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D007668:Kidney / Q000098:blood supply / Q000378:metabolism; D010456:Peptides, Cyclic / Q000494:pharmacology; D058910:Purinergic P2 Receptor Agonists; D051381:Rats; D018048:Receptors, Purinergic P2 / Q000378:metabolism; D058469:Receptors, Purinergic P2X; D014661:Vasoconstriction / Q000187:drug effects*; D014662:Vasoconstrictor Agents / Q000097:blood / Q000494:pharmacology*
D000227:Adenine Nucleotides; D000959:Antihypertensive Agents; D010456:Peptides, Cyclic; D058910:Purinergic P2 Receptor Agonists; D018048:Receptors, Purinergic P2; D058469:Receptors, Purinergic P2X; D014662:Vasoconstrictor Agents; C017991:adenosine 5'-tetraphosphate; C072247:cyclo(Trp-Asp-Pro-Val-Leu)